Physician profile
Seth D Levine
NPI 1174754659
$1,003.57
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $179 · 2022: $13.59.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $180.34 | 2019 | |
| Novo Nordisk INC | $124.11 | 2019-2020 | |
| Lilly USA, LLC | $101.26 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $100.24 | 2019 | |
| Amgen INC. | $98.10 | 2019-2020 | |
| Astellas Pharma US INC | $72.77 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.76 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $51.15 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $45.85 | 2019 | |
| Amarin Pharma, INC. | $30.38 | 2020 | |
| Allergan, INC. | $30.28 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $29.32 | 2019 | |
| Pfizer INC. | $27.03 | 2019-2020 | |
| Genzyme Corporation | $21.04 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.12 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $15.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.